Surface suppliers whose revenue is concentrated in a small number of buyers. The single-customer dependency view, computed from anonymised trade flows.
The catalog indexes 447 supplier-year buyer-concentration rows for 2024. Of these, 72 carry buyer-HHI above 5000 (the high-concentration threshold), 69 sit in the 1500-2500 low-concentration band, 88 in the 2500-5000 moderate band, and 218 are fragmented (HHI under 1500). Counterparty data is aggregated and anonymised by design; the catalog surfaces share concentration but never the named buyer. The high-concentration cohort is the continuity-risk view: a supplier dependent on one buyer is vulnerable to that buyer's BD decision.
| # | Supplier | Region | Buyer HHI 2024 | Distinct buyers | Top-buyer share |
|---|---|---|---|---|---|
| 1 | Chandra Bhagat Pharma | IN | 9802 HHI | 6 buyers | VAI |
| 2 | Chemeca Drugs | IN · multi-site | 9753 HHI | 9 buyers | VAI |
| 3 | Graviti Pharms | IN | 9614 HHI | 5 buyers | VAI |
| 4 | Tempo Scan Pacific | ID | 9394 HHI | 5 buyers | VAI |
| 5 | Rossari Biotech | IN | 9246 HHI | 8 buyers | VAI |
| 6 | Shreya Life Sciences | IN | 9211 HHI | 8 buyers | VAI |
| 7 | Chemplast Sanmar | IN | 9205 HHI | 10 buyers | VAI |
| 8 | Aurorium India | IN | 9180 HHI | 10 buyers | VAI |
| 9 | Darya Varia Laboratoria | ID | 8945 HHI | 8 buyers | VAI |
| 10 | AMN Life Science | IN | 8652 HHI | 10 buyers | VAI |
Upload or define your supplier base. PharmaDB resolves each to its corporate parent. Customs counterparty data is aggregated and anonymised per the data-use policy.
Buyer-side Herfindahl-Hirschman Index across the supplier's anonymised customer mix. Threshold bands: high (>5000), moderate (2500-5000), low (1500-2500), fragmented (<1500).
Citation-anchored cohort with buyer-HHI, distinct buyer count, and top-buyer share per supplier. Useful for the supplier-risk register and the BD acquisition-target search.
Buyer-HHI in four bands: high, moderate, low, fragmented. The high cohort is the continuity-risk inner ring; the moderate cohort is the second-source-opportunity zone.
Number of distinct buyers in the trailing year. A supplier with five distinct buyers and HHI 9500 is concentrated; the share lives in one buyer.
Procurement uses it for continuity-risk register; BD uses it as an acquirable single-customer business filter. Same data, two workflows.
Counterparty names are aggregated and anonymised. The catalog surfaces share concentration but never the named buyer. Aligns with the data-use policy and customs-licence terms.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Approximate supplier counts per buyer-HHI band · 2024 shipment year · live warehouse.
The buyer-concentration view is the continuity-risk and BD-acquirable filter in one. PharmaDB computes buyer-side HHI per supplier-year from aggregated and anonymised trade flows. The view is company_buyer_concentration joined to global_companies. Refresh cadence is quarterly.
HHI captures both the number of buyers and the share distribution in a single number. A supplier with five equal-share buyers has HHI 2000 (moderate); a supplier with five buyers but 90% to one has HHI 8200 (high). The single number is more useful than either count or top-share alone.
No. Counterparty data is aggregated and anonymised. The catalog surfaces share concentration but never the named buyer. The output respects customs-licence terms and the data-use policy for in-product surfacing.
The same data answers two different questions. Procurement teams use the high-concentration cohort as a continuity-risk register: a supplier dependent on one buyer is vulnerable. BD teams use the same cohort as acquirable single-customer businesses: a strategic acquirer can diversify the buyer base post-close.
Buyer-concentration refreshes quarterly because the HHI computation needs a stable trailing window. Each row carries the shipment year and the catalog as-of date. Underlying customs data refreshes weekly but the HHI rollup stabilises on a longer cycle.
It covers supplier-years with at least three distinct anonymised buyers in the trailing window. Single-buyer-only suppliers do not produce a meaningful HHI; they surface in a separate single-buyer-dependent flag.
Yes. The concentration analysis is filterable by molecule, lane, or industry vertical. Useful for a procurement team studying continuity risk in a specific therapeutic area or a BD team scoping acquisition targets in a specific molecule cluster.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.